

Jerome Boursier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5880486/publications.pdf>

Version: 2024-02-01

139
papers

10,811
citations

46918

47
h-index

32761

100
g-index

142
all docs

142
docs citations

142
times ranked

10343
citing authors

#	ARTICLE	IF	CITATIONS
1	The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. <i>Hepatology</i> , 2016, 63, 764-775.	3.6	1,029
2	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
3	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 394, 2184-2196.	6.3	818
4	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	1.8	676
5	Determination of reliability criteria for liver stiffness evaluation by transient elastography. <i>Hepatology</i> , 2013, 57, 1182-1191.	3.6	466
6	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
7	Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. <i>Hepatology</i> , 2016, 63, 1817-1827.	3.6	388
8	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2018, 378, 2171-2181.	13.9	383
9	Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 65, 570-578.	1.8	300
10	Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease. <i>PLoS ONE</i> , 2015, 10, e0127991.	1.1	261
11	Comparison of blood tests for liver fibrosis specific or not to NAFLD. <i>Journal of Hepatology</i> , 2009, 50, 165-173.	1.8	230
12	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
13	Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1033.	3.8	181
14	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 73, 252-262.	1.8	170
15	Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. <i>Liver International</i> , 2021, 41, 261-270.	1.9	155
16	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
17	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	3.7	142
18	Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1074-1084.	0.8	126

#	ARTICLE	IF	CITATIONS
19	Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. <i>Journal of Hepatology</i> , 2017, 66, 67-74.	1.8	123
20	Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2014, 60, 65-76.	3.6	118
21	Reproducibility of Liver Stiffness Measurement by Ultrasonographic Elastometry. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1263-1269.	2.4	113
22	Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. <i>Hepatology</i> , 2012, 55, 58-67.	3.6	112
23	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021, 74, 1109-1116.	1.8	112
24	Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease. <i>PLoS Pathogens</i> , 2015, 11, e1004559.	2.1	111
25	IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. <i>Hepatology</i> , 2014, 60, 1879-1890.	3.6	107
26	New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019, 71, 389-396.	1.8	107
27	The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. <i>Liver International</i> , 2009, 29, 1507-1515.	1.9	105
28	Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 693-701.	0.8	95
29	Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1352-1362.	1.9	94
30	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 614-625.	3.7	91
31	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	2.4	90
32	A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 1255-1263.	0.2	87
33	Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. <i>Gut</i> , 2015, 64, 1148-1157.	6.1	84
34	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	1.9	76
35	Nonalcoholic Fatty Liver Disease and the Gut Microbiome. <i>Clinics in Liver Disease</i> , 2016, 20, 263-275.	1.0	73
36	A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. <i>Journal of Hepatology</i> , 2017, 66, 1158-1165.	1.8	71

#	ARTICLE	IF	CITATIONS
37	Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: A meta-analysis with individual data. <i>Clinical Biochemistry</i> , 2008, 41, 1368-1376.	0.8	69
38	Long-term follow-up after endoscopic resection for superficial esophageal squamous cell carcinoma: a multicenter Western study. <i>Endoscopy</i> , 2019, 51, 298-306.	1.0	67
39	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	1.8	66
40	Comparison and Improvement of MELD and Child-Pugh Score Accuracies for the Prediction of 6-month Mortality in Cirrhotic Patients. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 580-585.	1.1	59
41	Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 28-38.	0.8	58
42	Radiologic versus Endoscopic Placement of Percutaneous Gastrostomy in Amyotrophic Lateral Sclerosis: Multivariate Analysis of Tolerance, Efficacy, and Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 527-533.	0.2	56
43	Screening for therapeutic trials and treatment indication in clinical practice: MACK, a new blood test for the diagnosis of fibrotic NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1387-1396.	1.9	55
44	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.	1.8	54
45	Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 527-537.	2.3	53
46	Incidental focal solid liver lesions: diagnostic performance of contrast-enhanced ultrasound and MR imaging. <i>European Radiology</i> , 2010, 20, 1715-1725.	2.3	52
47	Portosystemic collateral vessels in liver cirrhosis: a three-dimensional MDCT pictorial review. <i>Abdominal Radiology</i> , 2012, 37, 746-766.	1.0	52
48	Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. <i>European Radiology</i> , 2011, 21, 1719-1726.	2.3	49
49	IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. <i>Gut</i> , 2015, 64, 1466-1475.	6.1	49
50	FibroMeters: a family of blood tests for liver fibrosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 40-51.	0.9	47
51	Optimization and robustness of blood tests for liver fibrosis and cirrhosis. <i>Clinical Biochemistry</i> , 2010, 43, 1315-1322.	0.8	42
52	Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. <i>Liver International</i> , 2010, 30, 1346-1354.	1.9	41
53	Phenotyping of circulating extracellular vesicles (EVs) in obesity identifies large EVs as functional conveyors of Macrophage Migration Inhibitory Factor. <i>Molecular Metabolism</i> , 2018, 18, 134-142.	3.0	40
54	Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0238717.	1.1	40

#	ARTICLE	IF	CITATIONS
55	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2022, 71, 402-414.	6.1	39
56	Direct comparison of the specialised blood fibrosis tests FibroMeter ^{V2G} and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1214-1222.	1.9	38
57	Association Between Severity of Obstructive Sleep Apnea and Blood Markers of Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1657-1661.	2.4	37
58	Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver prognosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 178-188.	1.9	36
59	Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. <i>Gastroenterology</i> , 2020, 159, 791-793.e2.	0.6	36
60	Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1243-1251.e12.	2.4	32
61	Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. <i>Liver International</i> , 2014, 34, 907-917.	1.9	28
62	Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00023.	1.3	28
63	Large oesophageal varice screening by a sequential algorithm using a cirrhosis blood test and optionally capsule endoscopy. <i>Liver International</i> , 2018, 38, 84-93.	1.9	27
64	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , 2018, 278, 82-90.	0.4	27
65	Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 455-468.	1.8	26
66	Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. <i>PLoS ONE</i> , 2019, 14, e0221524.	1.1	26
67	Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD. <i>Hepatology</i> , 2021, 73, 2196-2205.	3.6	25
68	Noninvasive liver steatosis quantification using MRI techniques combined with blood markers. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 973-982.	0.8	24
69	Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat?. <i>Liver International</i> , 2012, 32, 875-877.	1.9	24
70	Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 654-660.	1.4	24
71	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2415.	1.0	24
72	Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities. <i>European Respiratory Journal</i> , 2018, 51, 1800601.	3.1	23

#	ARTICLE	IF	CITATIONS
73	Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis. <i>Sleep Medicine</i> , 2021, 77, 357-364.	0.8	23
74	Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. <i>BMC Gastroenterology</i> , 2011, 11, 132.	0.8	22
75	Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. <i>Diabetes and Metabolism</i> , 2016, 42, 364-367.	1.4	22
76	Spirulina Liquid Extract Protects against Fibrosis Related to Non-Alcoholic Steatohepatitis and Increases Ursodeoxycholic Acid. <i>Nutrients</i> , 2019, 11, 194.	1.7	20
77	Quantification of portalâ€“bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. <i>Modern Pathology</i> , 2014, 27, 1035-1045.	2.9	19
78	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 777-787.e17.	2.4	19
79	Case-finding strategies in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2021, 3, 100219.	2.6	19
80	A not so solitary fibrous tumor of the liver. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 716-720.	0.9	18
81	MRI measurement of liver fat content predicts the metabolic syndrome. <i>Diabetes and Metabolism</i> , 2013, 39, 314-321.	1.4	18
82	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , 2021, 47, 101272.	1.4	18
83	Liverâ€“related and extrahepatic events in patients with nonâ€“alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	1.9	18
84	Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G485-G495.	1.6	17
85	Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 974-981.	0.8	16
86	Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 991-1003.	1.9	16
87	Large Extracellular Vesicle-Associated Rap1 Accumulates in Atherosclerotic Plaques, Correlates With Vascular Risks and Is Involved in Atherosclerosis. <i>Circulation Research</i> , 2020, 127, 747-760.	2.0	16
88	Microbiotaâ€“derived extracellular vesicles and metabolic syndrome. <i>Acta Physiologica</i> , 2021, 231, e13600.	1.8	16
89	Anti-diabetic drugs and NASH: from current options to promising perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 813-825.	1.9	16
90	Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1750-1756.	1.4	15

#	ARTICLE	IF	CITATIONS
91	Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. <i>EClinicalMedicine</i> , 2020, 25, 100445.	3.2	15
92	Endoscopic treatment of painful chronic pancreatitis: Evaluation of a new flexible multiperforated plastic stent. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 801-805.	0.9	14
93	Clinical interpretation of Fibroscan® results: a real challenge. <i>Liver International</i> , 2010, 30, 1400-1402.	1.9	14
94	Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 1050-1060.	0.9	12
95	Reliability Criteria of Two-Dimensional Shear Wave Elastography: Analysis of 4277 Measurements in 788 Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 400-408.e10.	2.4	12
96	LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR4. <i>Metabolism: Clinical and Experimental</i> , 2021, 118, 154727.	1.5	12
97	Assessment of new hyaluronic acid assays and their impact on FibroMeter scores. <i>Clinica Chimica Acta</i> , 2011, 412, 347-352.	0.5	11
98	Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1240-1249.	1.4	11
99	Criteria to Determine Reliability of Noninvasive Assessment of Liver Fibrosis With Virtual Touch Quantification. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 164-171.e5.	2.4	11
100	Quality criteria for the measurement of liver stiffness. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101761.	0.7	10
101	Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. <i>Liver International</i> , 2022, 42, 1330-1343.	1.9	10
102	Combination of fibrosis tests: Sequential or synchronous?. <i>Hepatology</i> , 2009, 50, 656-657.	3.6	9
103	Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 381-394.	1.6	8
104	MRI versus histological methods for time course monitoring of steatosis amount in a murine model of NAFLD. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 915-922.	1.8	8
105	Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?. <i>Journal of Hepatology</i> , 2017, 66, 304-312.	1.8	8
106	Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101769.	0.7	8
107	Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101848.	0.7	8
108	Treatment of liver fibrosis: Clinical aspects. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 958-966.	0.9	7

#	ARTICLE	IF	CITATIONS
109	Liver fibrogenesis and genetic factors. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S3-S9.	0.7	7
110	Cirrhosis Diagnosis and Liver Fibrosis Staging. Journal of Clinical Gastroenterology, 2015, 49, 512-519.	1.1	7
111	Noninvasive Tests of Liver Fibrosis and Their Combination in Nonalcoholic Fatty Liver Disease: From Selected Patients to Real-Life Populations. Hepatology, 2019, 70, 1500-1502.	3.6	7
112	Non-invasive diagnosis of patients with "at-risk"™ NAFLD : only fibrosis counts?. Gut, 2020, 69, 1164-1165.	6.1	7
113	Cross-linkage between bacterial taxonomy and gene functions: a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 722-732.	1.9	7
114	Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD. Seminars in Liver Disease, 2022, 42, 313-326.	1.8	7
115	Screening for significant chronic liver disease by using three simple ultrasound parameters. European Journal of Radiology, 2015, 84, 1466-1472.	1.2	6
116	Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C. World Journal of Hepatology, 2017, 9, 310.	0.8	6
117	Doppler ultrasonography devices, including elastography, allow for accurate diagnosis of severe liver fibrosis. European Journal of Radiology, 2018, 108, 133-139.	1.2	5
118	A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis. Hepatology Communications, 2018, 2, 455-466.	2.0	4
119	Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD _{Na} ≥ 12 over 5 years of follow-up. Liver International, 2021, 41, 168-179.	1.9	4
120	Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. PLoS ONE, 2022, 17, e0266965.	1.1	4
121	Metastatic hepatocellular carcinoma: When surgery and successive palliative treatments lead to remission. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, e19-e22.	0.7	3
122	Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 349-355.	0.7	3
123	Ultrasonographic elastometry vs. blood tests for the diagnosis of cirrhosis: A Pyrrhic victory?. Journal of Hepatology, 2009, 51, 228-229.	1.8	2
124	The combination of Fibroscan with blood markers in the fibrometer/VCTE significantly reduces the use of liver biopsy for the assessment of advanced fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2017, 66, S161-S162.	1.8	2
125	Noninvasive diagnosis of liver fibrosis in NAFLD: Tips tricks. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 658-662.	0.7	2
126	Apple Supplementation Improves Hemodynamic Parameter and Attenuates Atherosclerosis in High-Fat Diet-Fed Apolipoprotein E-Knockout Mice. Biomedicines, 2020, 8, 495.	1.4	2

#	ARTICLE	IF	CITATIONS
127	Obstructive sleep apnoea and non-alcoholic fatty liver disease: Which patients should be referred to hepatologists?. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e90-e92.	0.7	1
128	Quality Criteria for Liver Stiffness Measurement by Transient Elastography. , 2020, , 479-494.		1
129	Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis" 2021 update". Journal of Hepatology, 2022, 76, 251-252.	1.8	1
130	Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle. Hepatology, 2022, 75, 782-784.	3.6	1
131	Which would you prefer for a liver fibrosis test: A limited fixed menu or a gourmet buffet?. Gastroentérologie Clinique Et Biologique, 2009, 33, 388-389.	0.9	0
132	Response to Munteanu et al.. American Journal of Gastroenterology, 2011, 106, 1853-1854.	0.2	0
133	The <sc>CUPIC</sc> algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. Journal of Viral Hepatitis, 2015, 22, 1002-1010.	1.0	0
134	Reply. Hepatology, 2016, 64, 994-995.	3.6	0
135	Editorial: combining elastography with blood test for fibrosis assessment in chronic hepatitis C "authors" reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1276-1277.	1.9	0
136	Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM VCTE algorithm" and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes". Journal of Hepatology, 2018, 68, 605-606.	1.8	0
137	Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease and Liver Diseases: A Meta-Analysis of Individual Patient Data. , 2019, , .		0
138	Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward". Journal of Hepatology, 2020, 73, 466-467.	1.8	0
139	Biomarkers of liver fibrosis may behave differently depending on associated co-morbidities: need to consider the context of use. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0